IPO Comments Regarding USPTO Proposed Trademark Fee Schedule
IPO Comments Regarding USPTO Proposed Trademark Fee Schedule
IPO Comments to Patent Public Advisory Committee re: USPTO Proposed Patent Fee Adjustments
IPO Comments to Patent Public Advisory Committee re: USPTO Proposed [...]
IPO Comments to USPTO Regarding Artificial Intelligence and Inventorship
IPO Comments to USPTO Regarding Artificial Intelligence and Inventorship
IPO Comments to FTC Regarding Non-Compete Clause Rule, Matter No. P201200
IPO Comments to FTC Regarding Non-Compete Clause Rule, Matter No. [...]
IPO Comments on the Updated EPO Guidelines for Examination
IPO Comments on the Updated EPO Guidelines for Examination
IPO Testimony to U.S. ITC Regarding COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities
IPO Testimony to U.S. ITC Regarding COVID-19 Diagnostics and Therapeutics: [...]
IPO Response to Questions Re: USTR 2023 Special 301 Review
IPO Response to Questions Re: USTR 2023 Special 301 Review
IPO Comments to CNIPA on Draft Amendment to the Trademark Law
IPO Comments to CNIPA on Draft Amendment to the Trademark [...]
IPO’s Comments on the Draft 2022-2026 USPTO Strategic Plan
IPO’s Comments on the Draft 2022-2026 USPTO Strategic Plan
IPO Comments on Joint USPTO–FDA Collaboration Initiatives
IPO Comments on Joint USPTO–FDA Collaboration Initiatives
Posts tagged here will show on the testimony and comments page.